Maria Curcio Bishop

Interests

Teaching

1. Graduate medical education2. Post-graduate hematology/oncology education3. Medical ethics and palliative and supportive care4. Global cancer education

Research

1. Central nervous system malignancies2. Palliative and supportive care3. Global cancer education

Courses

No activities entered.

Scholarly Contributions

Journals/Publications

• Marcarian, H. Q., Sivakoses, A., Arias, A. M., Ihedioha, O. C., Lee, B. R., Bishop, M. C., & Bothwell, A. L. (2025). Renal cancer cells acquire immune surface protein through trogocytosis and horizontal gene transfer. PLOS ONE, 20(Issue 5). doi:10.1371/journal.pone.0325043
  More info

  Trogocytosis is an underappreciated phenomenon that shapes the immune microenvironment surrounding many types of solid tumors. The consequences of membrane-bound proteins being deposited from a donor immune cell to a recipient cancer cell via trogocytosis are still unclear. Here, we report that human clear cell renal carcinoma tumors stably express the lymphoid markers CD45, CD56, CD14, and CD16. Flow cytometry performed on fresh kidney tumors revealed consistent CD45 expression on tumor cells, as well as varying levels of the other markers mentioned previously. These results were consistent with our immunofluorescent analysis, which also revealed colocalization of lymphoid markers with carbonic anhydrase 9, a standard kidney tumor marker. RNA analysis showed a significant upregulation of genes typically associated with immune cells by tumor cells. Finally, we show evidence of chromosomal DNA being transferred from immune cells to tumor cells through physical contact. This horizontal gene transfer has transcriptional consequences in the recipient tumor cell, resulting in a fusion phenotype that expresses both immune and cancer specific proteins. This work demonstrates a novel mechanism by which tumor cell protein expression is altered through the acquisition of surface membrane fragments and genomic DNA from infiltrating lymphocytes. These results alter the way in which we understand tumor-immune cell interactions and may reveal new insights into the mechanisms by which tumors develop. Additionally, further studies into trogocytosis and other mechanisms of contact-mediated cellular transfer will help push the field towards the next generation of immunotherapies and biomarkers for treating renal cell carcinoma and other cancers.
• Rajeswaran, T., Dawdy, K., Bishop, M., Amiel, G., Heneghan, K., Khader, J., de Vries, J., Silva, F. S., Wiljer, D., & Szumacher, E. (2024). An Exploration of the Pillars of Leadership in Cancer Education. Journal of Cancer Education, 39(Issue 3). doi:10.1007/s13187-024-02409-w
  More info

  Leadership plays a key role in cancer education (CE) and the success of its practices. Leaders in CE must effectively use their leadership skills to be able to communicate, collaborate, and educate their team members. There is a lack of formalized and standardized curriculums for institutions in developing leadership programs, including what themes to focus on in CE. In this article, the authors describe key pillars of leadership in CE that have presented themselves throughout their experience and within the literature. A search was conducted using the Ovid MEDLINE® database and articles were reviewed for eligibility. In this review, thirty articles were selected for their relevance to CE. With this literature search and the authors' reflections, four pillars of leadership in CE were identified: (1) leadership development, (2) collaboration, (3) diversity and equity, and (4) implementation. Within these themes, key areas of importance were discussed further, and barriers to CE leadership were identified. By reflecting upon pillars of leadership in CE, this article may be helpful for developing future leadership programs within CE. It is vital that initiatives continue to be held and barriers are addressed to increase leadership effectiveness within CE.
• Bishop, M. C. (2023). The American Association for Cancer Education Academy of Fellows Welcomes Five New Fellows; Margaret Hay Edwards Achievement Medal Awarded. Journal of Cancer Education, 38(Issue 2). doi:10.1007/s13187-023-02276-x
• Warsi, A., Dawdy, K., Bishop, M., Khader, J., Amiel, G., Heneghan, K., Wiljer, D., & Szumacher, E. (2023). Leadership, Leading, and Influencing Change in Cancer Education: Development and Assessment of a Pilot Leadership Workshop in Cancer Education for Interdisciplinary Healthcare Staff. Journal of Cancer Education, 38(Issue 2). doi:10.1007/s13187-022-02179-3
  More info

  Effective leaders in healthcare settings create a motivating work environment, initiate changes in practice, and facilitate interdisciplinary collaboration to advance patient-centered care. Health professionals in cancer education need leadership development to meet the continued rise in cancer cases and to keep up with the rapid biomedical and technological advances in global cancer care. In addition, leadership development in cancer education supports interprofessional collaboration, optimizes patient engagement, and provides mentorship opportunities necessary for career advancement and skill development. The identified benefits from leadership development in cancer education led to the creation of an interactive pilot leadership workshop titled “Essential Skills in Cancer Education: Leadership, Leading, and Influencing Change in Cancer Education,” held at the International Cancer Education Conference in October 2020. The workshop was led by global leaders in cancer education and utilized lectures, mentorship opportunities, interactive case studies, and individual learning projects to develop leadership skills in multidisciplinary oncology professionals. Fifteen attendees from diverse educational backgrounds and levels of experience participated in the virtual leadership workshop and mentorship program. Following the workshop, participants reported an increase in knowledge regarding how to use different leadership styles, initiate changes in practice, and apply leadership skills in their career development and at their institutions. The feedback received from participants through post-workshop evaluations was overall positive and demonstrated an interest for more leadership development opportunities in cancer education. This pilot workshop shows that leadership is a valuable and teachable skill that will benefit both healthcare professionals and patients in the field of cancer education.
• Bishop, M. C., & Briehl, M. M. (2022). A Successful Program to Promote Equity in Cancer Care for American Indians. Journal of Cancer Education, 37(Issue 1). doi:10.1007/s13187-021-02129-5
• Bishop, M. C., & Heneghan, K. (2022). Honoring Two New Members of the American Association for Cancer Education Academy of Fellows. Journal of cancer education : the official journal of the American Association for Cancer Education, 37(Issue 3). doi:10.1007/s13187-022-02167-7
• Trejo, M. J., Batai, K., Chen, Y., Brezina, S., Chow, H. H., Ellis, N., Lance, P., Hsu, C. H., Pogreba-Brown, K., Bishop, M., Gsur, A., & Jacobs, E. T. (2022). Genome-Wide Association Study of Metachronous Colorectal Adenoma Risk among Participants in the Selenium Trial. Nutrition and Cancer, 75(Issue 1). doi:10.1080/01635581.2022.2096910
  More info

  Genetic variants related to colorectal adenoma may help identify those who are at highest risk of colorectal cancer development or illuminate potential chemopreventive strategies. The purpose of this genome-wide association study was to identify genetic variants that are associated with risk of developing a metachronous colorectal adenoma among 1,215 study participants of European descent from the Selenium Trial. Associations of variants were assessed with logistic regression analyses and validated in an independent case-control study population of 1,491 participants from the Colorectal Cancer Study of Austria (CORSA). No statistically significant genome-wide associations between any variant and metachronous adenoma were identified after correction for multiple comparisons. However, an intron variant of FAT3 gene, rs61901554, showed a suggestive association (P = 1.10 × 10−6) and was associated with advanced adenomas in CORSA (P = 0.04). Two intronic variants, rs12728998 and rs6699944 in NLRP3 were also observed to have suggestive associations with metachronous lesions (P = 2.00 × 10−6) in the Selenium Trial and were associated with advanced adenoma in CORSA (P = 0.03). Our results provide new areas of investigation for the genetic basis of the development of metachronous colorectal adenoma and support a role for FAT3 involvement in the Wnt/β-catenin pathway leading to colorectal neoplasia. Trial Registration number: NCT00078897 (ClinicalTrials.gov).
• Bishop, M. C. (2021). New Programs to Promote Global Cancer Education. Journal of Cancer Education, 36(Issue 4). doi:10.1007/s13187-021-02061-8
• Meade, C. D., & Bishop, M. C. (2021). New Journal Section: Cancer, Culture, and Literacy. Journal of Cancer Education, 36(Issue 2). doi:10.1007/s13187-021-01979-3
• Bishop, M. C. (2020). The Veterans Health Administration's Contribution to Cancer Education.. Journal of cancer education : the official journal of the American Association for Cancer Education, 35(1), 1-2. doi:10.1007/s13187-019-01679-z
• Bishop, M. (2019). An Opportunity to Share. Journal of Cancer Education, 34, 628.
• Bishop, M. (2019). An Opportunity to Share. Journal of Cancer Education, Published Online. doi:DOI: 10.1007/s13187-019-01584-5
• Bishop, M. C. (2019). An Opportunity to Share. Journal of cancer education : the official journal of the American Association for Cancer Education, 34(Issue 4). doi:10.1007/s13187-019-01584-5
• Bishop, M., Veto, J., Michael, A., & Hamilton, J. (2019). The Art of Journal Writing and Reviewing: Keys to Success. Journal of Cancer Education, Suppl1: S13, 34.
• Bishop, M. (2018). Gifts from the Past. Journal of Cancer Education, 1425-1426. doi:10.1007/s13187-018-1425-6.
  More info

  Editorial
• Bishop, M. (2018). Mentorship in Medicine and other Health Professions. Journal of Cancer Education, 1360-1366. doi:10.1007/s13187-018-1360-6.
  More info

  Review Article
• Bishop, M. C. (2018). Gifts from the Past. Journal of Cancer Education, 33(Issue 5). doi:10.1007/s13187-018-1425-6
• Bishop, M., & Szumacher, E. (2014). Career Counseling for Medical Oncology and Radiation Oncology Postgraduate Trainees. Journal of Cancer Education, 29(s1).
• Rogowitz, E., Babiker, H. M., Kanaan, M., Millius, R. A., Ringenberg, Q. S., & Bishop, M. (2014). Neuroblastoma of the elderly, an oncologist's nightmare: Case presentation, literature review and SEER database analysis. Experimental Hematology and Oncology, 3(Issue 1). doi:10.1186/2162-3619-3-20
  More info

  Neuroblastoma is considered a pediatric malignancy as over 95% of cases are diagnosed in patients ≤10 years old. This cancer is extremely rare in elderly patients. We conducted a Surveillance, Epidemiology, and End Results (SEER) database analysis in the USA between 1973-2007 that revealed only 35 elderly patients (>60 years of age) with neuroblastoma of whom only 2 patients had primary mediastinal neuroblastoma. There is a paucity of treatment and survival outcomes data for the elderly owing to the rarity of neuroblastoma in this population. Currently there are no standard guidelines or protocols for treatment of adult neuroblastoma. We report a rare and challenging case of an 86-year old patient presenting with mediastinal neuroblastoma and syndrome of inappropriate antidiuretic hormone secretion (SIADH) successfully treated with resection. Herein, we also provide a review of the literature and updated survival data on neuroblastoma based on results of our SEER database review. © 2014 Rogowitz et al.; licensee BioMed Central Ltd.
• Rogowitz, E., Babiker, H. M., Kanaan, M., Millius, R. A., Ringenberg, Q. S., & Bishop, M. (2014). Neuroblastoma of the elderly, an oncologist's nightmare: case presentation, literature review and SEER database analysis. Experimental hematology & oncology, 3, 20.
  More info

  Neuroblastoma is considered a pediatric malignancy as over 95% of cases are diagnosed in patients ≤10 years old. This cancer is extremely rare in elderly patients. We conducted a Surveillance, Epidemiology, and End Results (SEER) database analysis in the USA between 1973-2007 that revealed only 35 elderly patients (>60 years of age) with neuroblastoma of whom only 2 patients had primary mediastinal neuroblastoma. There is a paucity of treatment and survival outcomes data for the elderly owing to the rarity of neuroblastoma in this population. Currently there are no standard guidelines or protocols for treatment of adult neuroblastoma. We report a rare and challenging case of an 86-year old patient presenting with mediastinal neuroblastoma and syndrome of inappropriate antidiuretic hormone secretion (SIADH) successfully treated with resection. Herein, we also provide a review of the literature and updated survival data on neuroblastoma based on results of our SEER database review.
• Taverna, J. A., Babiker, H. M., Yun, S., Bishop, M. C., Lau-Braunhut, S., Meyer, P. N., & Enzler, T. (2014). The great masquerader of malignancy: Chronic intestinal pseudo-obstruction. Biomarker Research, 2(Issue 1). doi:10.1186/s40364-014-0023-y
  More info

  Paraneoplastic syndromes can precede the initial manifestation and diagnosis of cancer. Paraneoplastic syndromes are a heterogeneous group of disorders caused by mechanisms other than the local presence of tumor cells. These phenomena are mediated by humoral factors secreted by tumor cells or by tumor mediated immune responses. Among paraneoplastic syndromes, chronic intestinal pseudo-obstruction (CIPO) is rare and represents a particularly difficult clinical challenge. Paraneoplastic CIPO is a highly morbid syndrome characterized by impaired gastrointestinal propulsion with symptoms and signs of mechanical bowel obstruction. Clinical outcomes of paraneoplastic CIPO are often deleterious. The current standard of care for the management of CIPO includes supportive treatment with promotility and anti-secretory agents. However, the majority of patients with CIPO eventually require the resection of the non-functioning gut segment. Here, we present a 62-year-old patient with anti-Hu antibody associated paraneoplastic CIPO and underlying small cell lung cancer who underwent treatment with cisplatin and etoposide. Herein, we discuss diagnosis, prognosis, proposed mechanisms, treatment options, and future potential therapeutic strategies of paraneoplastic CIPO.
• Taverna, J. A., Babiker, H. M., Yun, S., Bishop, M. C., Lau-Braunhut, S., Meyer, P. N., & Enzler, T. (2014). The great masquerader of malignancy: chronic intestinal pseudo-obstruction. Biomarker research, 2(1), 23.
  More info

  Paraneoplastic syndromes can precede the initial manifestation and diagnosis of cancer. Paraneoplastic syndromes are a heterogeneous group of disorders caused by mechanisms other than the local presence of tumor cells. These phenomena are mediated by humoral factors secreted by tumor cells or by tumor mediated immune responses. Among paraneoplastic syndromes, chronic intestinal pseudo-obstruction (CIPO) is rare and represents a particularly difficult clinical challenge. Paraneoplastic CIPO is a highly morbid syndrome characterized by impaired gastrointestinal propulsion with symptoms and signs of mechanical bowel obstruction. Clinical outcomes of paraneoplastic CIPO are often deleterious. The current standard of care for the management of CIPO includes supportive treatment with promotility and anti-secretory agents. However, the majority of patients with CIPO eventually require the resection of the non-functioning gut segment. Here, we present a 62-year-old patient with anti-Hu antibody associated paraneoplastic CIPO and underlying small cell lung cancer who underwent treatment with cisplatin and etoposide. Herein, we discuss diagnosis, prognosis, proposed mechanisms, treatment options, and future potential therapeutic strategies of paraneoplastic CIPO.
• Agarwal, A., Larsen, B. T., Buadu, L. D., Dunn, J., Crawford, R., Daniel, J., & Bishop, M. C. (2013). Denosumab chemotherapy for recurrent giant-cell tumor of bone: a case report of neoadjuvant use enabling complete surgical resection. Case reports in oncological medicine, 2013, 496351.
  More info

  Giant-cell tumor of the bone (GCTB) is a rare neoplasm that affects young adults. The tumor is generally benign but sometimes can be locally aggressive. There are no standardized approaches to the treatment of GCTB. Recently, the RANKL inhibitor denosumab has shown activity in this tumor type. We present the case of a young female who presented with locally advanced disease and was successfully managed with the neoadjuvant use of denosumab allowing for surgical resection of the tumor that was previously deemed unresectable. Following surgery, the patient is being managed with continued use of denosumab as 'maintenance,' and she continues to be free of disease. Our case highlights a novel approach for the management of locally advanced and aggressive giant cell tumor of the bone.
• Badger, T. A., Segrin, C., Figueredo, A. J., Harrington, J., Sheppard, K., Passalacqua, S., Pasvogel, A., & Bishop, M. (2013). Who benefits from a psychosocial counselling versus educational intervention to improve psychological quality of life in prostate cancer survivors?. Psychology & health, 28(3), 336-54.
  More info

  We examined selected survivor characteristics to determine what factors might moderate the response to two psychosocial interventions.
• Badger, T. A., Segrin, C., Figueredo, A. J., Harrington, J., Sheppard, K., Passalacqua, S., Pasvogel, A., & Bishop, M. (2013). Who benefits from a psychosocial counselling versus educational intervention to improve psychological quality of life in prostate cancer survivors?. Psychology and Health, 28(Issue 3). doi:10.1080/08870446.2012.731058
  More info

  Objective: We examined selected survivor characteristics to determine what factors might moderate the response to two psychosocial interventions.Design: Seventy-one prostate cancer survivors (PCSs) were randomly assigned to either a telephone-delivered health education (THE) intervention or a telephone-delivered interpersonal counselling (TIP-C) intervention.Measures: Psychological quality of life (QOL) outcomes included depression, negative and positive affect, and perceived stress.Results: For three of the psychological outcomes (depression, negative affect and stress), there were distinct advantages from participating in THE. For example, more favourable depression outcomes occurred when men were older, had lower prostate specific functioning, were in active chemotherapy, had lower social support from friends and lower cancer knowledge. Participating in the TIP-C provided a more favourable outcome for positive affect when men had higher education, prostate specific functioning, social support from friends and cancer knowledge.Conclusion: Unique survivor characteristics must be considered when recommending interventions that might improve psychological QOL in PCSs. Future research must examine who benefits most and from what components of psychosocial interventions to enable clinicians to recommend appropriate psychosocial care. © 2013 Copyright Taylor and Francis Group, LLC.
• Larsen, B. T., Bishop, M. C., Hunter, G. C., & Renner, S. W. (2013). Low-grade, metastasizing splenic littoral cell angiosarcoma presenting with hepatic cirrhosis and splenic artery aneurysm. International journal of surgical pathology, 21(6), 618-26.
  More info

  The behavior of littoral cell neoplasms ranges from benign (littoral cell angioma, LCA) to highly malignant (angiosarcoma). Two unusual cases of low-grade metastatic littoral cell angiosarcoma (LCAS) have been reported with late recurrence and bulky metastases. We present the third case of this rare neoplasm in a 38-year-old man with cirrhosis and a large splenic artery aneurysm, without extrasplenic masses. The spleen showed nodules resembling LCA, immunoreactive for CD31, factor VIII, CD68, and CD163 but not CD8 or CD34. Also present were solid areas of immunophenotypically identical bland spindle cells, although lighter CD31 immunostaining distinguished them from LCA-like angiomatous channels. Similar cells diffusely infiltrated the cirrhotic liver. After splenectomy, pancytopenia resolved, and he is asymptomatic 19 months later. Low-grade LCAS is a previously unreported cause of cirrhosis and may metastasize without forming masses. In cases of LCA, CD31 immunohistochemistry may facilitate detection of LCAS and indicate metastatic potential.
• Badger, T. A., Segrin, C., Figueredo, A. J., Harrington, J., Sheppard, K., Passalacqua, S., Pasvogel, A., & Bishop, M. (2011). Psychosocial interventions to improve quality of life in prostate cancer survivors and their intimate or family partners. Quality of Life Research, 20(Issue 6). doi:10.1007/s11136-010-9822-2
  More info

  Purpose: The primary purpose was to test the effectiveness of two telephone-delivered psychosocial interventions for maintaining and improving quality of life (QOL) (psychological, physical, social, and spiritual well-being) among 71 prostate cancer survivors and the 70 intimate or family partners who were supporting them in their recovery. Methods: This study used a three-wave repeated measures experimental design. Both the interpersonal counseling intervention (TIP-C) and health education attention condition (HEAC) were delivered using the telephone. Results: Improvements in depression, negative affect, stress, fatigue, and spiritual well-being were significantly higher for survivors in the HEAC than for those in the TIP-C condition. Partners in the HEAC condition showed significantly greater improvements in depression, fatigue, social support from family members, social well-being, and spiritual well-being compared to partners in the TIP-C condition. The results revealed superior outcomes for those assigned to the HEAC intervention. Conclusions: The psychosocial interventions in this study were effective in maintaining or improving the QOL for prostate cancer survivors and their partners. Both the survivor and their intimate partner or family member benefitted from the interventions. Future research is needed to determine the optimal timing and client characteristics for each intervention. © 2010 Springer Science+Business Media B.V.
• Badger, T. A., Segrin, C., Figueredo, A. J., Harrington, J., Sheppard, K., Passalacqua, S., Pasvogel, A., & Bishop, M. (2011). Psychosocial interventions to improve quality of life in prostate cancer survivors and their intimate or family partners. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 20(6), 833-44.
  More info

  The primary purpose was to test the effectiveness of two telephone-delivered psychosocial interventions for maintaining and improving quality of life (QOL) (psychological, physical, social, and spiritual well-being) among 71 prostate cancer survivors and the 70 intimate or family partners who were supporting them in their recovery.
• Nguyen, N. P., Bishop, M., Borok, T. J., Welsh, J., Hamilton, R., Cohen, D., Nguyen, L. M., & Vincent, V. (2010). Pattern of failure following chemoradiation for locally advanced non-small cell lung cancer: potential role for stereotactic body radiotherapy. Anticancer research, 30(3), 953-61.
  More info

  Standard of care for locally advanced non-small cell lung cancer has been concurrent chemoradiation. However, optimal chemotherapy regimen, radiation therapy dose and treatment volume have not been clearly defined despite 30 years of controlled clinical trials. This review analyzes survival and failure pattern reported from randomized studies of chemoradiation for non-small cell lung cancer. Despite introduction of new chemotherapy agents, survival remained poor; rates of both locoregional failures and distant metastasis remained high. The current radiation dose appears insufficient to reliably establish local control. Stereotactic body radiotherapy may allow radiation dose escalation and should be tested in future clinical trials.
• Nguyen, N. P., Bishop, M., Borok, T. J., Welsh, J., Hamilton, R., Cohen, D., Nguyen, L. Y., & Vincent, V. H. (2010). Pattern of failure following chemoradiation for locally advanced non-small cell lung cancer: Potential role for stereotactic body radiotherapy. Anticancer Research, 30(Issue 3).
  More info

  Standard of care for locally advanced non-small cell lung cancer has been concurrent chemoradiation. However, optimal chemotherapy regimen, radiation therapy dose and treatment volume have not been clearly defined despite 30 years of controlled clinical trials. This review analyzes survival and failure pattern reported from randomized studies of chemoradiation for non-small cell lung cancer. Despite introduction of new chemotherapy agents, survival remained poor; rates of both locoregional failures and distant metastasis remained high. The current radiation dose appears insufficient to reliably establish local control. Stereotactic body radiotherapy may allow radiation dose escalation and should be tested in future clinical trials.
• Dayani, P. N., Bishop, M. C., Black, K., & Zeltzer, P. M. (2004). Desferoxamine (DFO) - Mediated iron chelation: Rationale for a novel approach to therapy for brain cancer. Journal of Neuro-Oncology, 67(Issue 3). doi:10.1023/b:neon.0000024238.21349.37
  More info

  Iron homeostasis is crucial to normal cell metabolism, and its deficiency or excess is associated with numerous disease states. The association of increased iron load with cancer may be due to several factors including free radical production, reduction of the body's protective mechanism to combat oxidative stress, inhibition of immune systems, inhibition of essential nutrient functions, facilitation of cancer growth, suppression of antitumor actions of macrophages, and lowering of the ratio of T4-T8 positive lymphocytes. Antiproliferative effects of desferoxamine (DFO) both in vitro and in vivo are mediated by an intracellular pool of iron that is necessary for DNA synthesis rather than prevention of iron uptake from transferrin. Several clinical studies have shown it to have antitumor activity in the treatment of neuroblastoma, leukemia, bladder carcinoma, and hepatocellular carcinoma. Human neural tumor cells are susceptible to the effects of DFO. Continued study of DFO is necessary to further elucidate its antineoplastic profile and its use as an adjunct to current chemotherapy regimens. Given the lack of satisfactory treatment of central nervous system neoplasms, DFO could serve as an important tool in the management of such cancers. © 2004 Kluwer Academic Publishers.
• Dayani, P. N., Bishop, M. C., Black, K., & Zeltzer, P. M. (2004). Desferoxamine (DFO)--mediated iron chelation: rationale for a novel approach to therapy for brain cancer. Journal of neuro-oncology, 67(3), 367-77.
  More info

  Iron homeostasis is crucial to normal cell metabolism, and its deficiency or excess is associated with numerous disease states. The association of increased iron load with cancer may be due to several factors including free radical production, reduction of the body's protective mechanism to combat oxidative stress, inhibition of immune systems, inhibition of essential nutrient functions, facilitation of cancer growth, suppression of antitumor actions of macrophages, and lowering of the ratio of T4-T8 positive lymphocytes. Antiproliferative effects of desferoxamine (DFO) both in vitro and in vivo are mediated by an intracellular pool of iron that is necessary for DNA synthesis rather than prevention of iron uptake from transferrin. Several clinical studies have shown it to have antitumor activity in the treatment of neuroblastoma, leukemia, bladder carcinoma, and hepatocellular carcinoma. Human neural tumor cells are susceptible to the effects of DFO. Continued study of DFO is necessary to further elucidate its antineoplastic profile and its use as an adjunct to current chemotherapy regimens. Given the lack of satisfactory treatment of central nervous system neoplasms, DFO could serve as an important tool in the management of such cancers.
• Bishop, M. C., Gores, F. A., Stempel, J., Torrington, P., Tynan, C., Jaskar, D., & Garewal, H. S. (2000). A collaborative end-of-life care curriculum. American Journal of Hospice and Palliative Medicine®, 17(2), 137-140. doi:10.1177/104990910001700214

Presentations

• Bishop, M. (2019, May). Journal of Cancer Education: Opportunities for Mentorship. European Association for Cancer Education 32nd Annual Scientific Meeting. Porto, Portugal: European Association for Cancer Education.
  More info

  I presented a workshop that addressed mentoring opportunities journal authors and reviewers.
• Bishop, M. (2019, September). Insights into Authorship and the Peer Review Process. International Cancer Education Workshop. Salt Lake City, Utah: International Cancer Education.
• Bishop, M. (2018, October, 2018). Developing a distance mentoring program with an international perspective impacting inter-professional global cancer training and care.. 2018 World Cancer Congress, UICC. Kuala Lumpur, Malaysia: Internation Union for Cancer Control.
  More info

  Accepted AbstractPresented at the World Cancer Congress

Others

• Bishop, M. (2020, January). The Veterans Health Administration's Contribution to Cancer Education. Journal of Cancer Education.
  More info

  Editorial https://doi.org/10.1007/s13187-019-01679-z